Who are DRSP-EE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): YAZ®, norelgestromin + ethinyl estradiol, Kariva®, Drospirenone / Estetrol, Female Contraceptive, Drospirenone Ethinyl estradiol Myo-inositol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/drsp-ee.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

DRSP-EE — Competitive Intelligence Brief

DRSP-EE (DRSP-EE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oral contraceptive (combined hormonal contraceptive). Area: Contraception / Gynecology.

phase 3 Oral contraceptive (combined hormonal contraceptive) Progesterone receptor, estrogen receptor Contraception / Gynecology Small molecule Live · refreshed every 30 min

Target snapshot

DRSP-EE (DRSP-EE) — Organon and Co. DRSP-EE is a combined oral contraceptive containing drospirenone (a progestin) and ethinyl estradiol (an estrogen) that prevents ovulation and alters cervical mucus to inhibit fertilization.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DRSP-EE TARGET	DRSP-EE	Organon and Co	phase 3	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor
YAZ®	YAZ®	Teva Pharmaceuticals USA	marketed	Oral contraceptive (combined estrogen-progestin)	Progesterone receptor, estrogen receptor, mineralocorticoid receptor
norelgestromin + ethinyl estradiol	norelgestromin + ethinyl estradiol	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	marketed	Combined oral contraceptive (progestin + estrogen)	Progesterone receptor, estrogen receptor
Kariva®	Kariva®	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor
Drospirenone / Estetrol	Drospirenone / Estetrol	University of Palermo	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
Female Contraceptive	Female Contraceptive	Italfarmaco	marketed	Hormonal contraceptive	Progesterone receptor, estrogen receptor
Drospirenone Ethinyl estradiol Myo-inositol	Drospirenone Ethinyl estradiol Myo-inositol	AGUNCO Obstetrics and Gynecology Centre	marketed	Oral contraceptive with insulin sensitizer	Progesterone receptor, estrogen receptor, inositol signaling pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oral contraceptive (combined hormonal contraceptive) class)

Bayer · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Organon and Co · 1 drug in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class
Virginia Commonwealth University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DRSP-EE — Competitive Intelligence Brief. https://druglandscape.com/ci/drsp-ee. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab